|Bid||11.19 x 2900|
|Ask||0.00 x 1100|
|Day's Range||16.81 - 17.80|
|52 Week Range||9.50 - 20.83|
|Beta (5Y Monthly)||1.69|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 12, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||25.00|
Terren Peizer became the CEO of Catasys, Inc. (NASDAQ:CATS) in 2003. First, this article will compare CEO compensation...
A whopping number of 13F filings filed with U.S. Securities and Exchange Commission has been processed by Insider Monkey so that individual investors can look at the overall hedge fund sentiment towards the stocks included in their watchlists. These freshly-submitted public filings disclose money managers’ equity positions as of the end of the three-month period […]
Catasys, Inc. (NASDAQ: CATS) ("Catasys" or the "Company"), a leading AI and technology-enabled healthcare company, today announced the expansion of its OnTrak-A solution with a leading national health plan into California beginning January 31, 2020. This expansion ensures that eligible commercial members of the health plan in California will have access to critical behavioral healthcare to help them better manage chronic disease. This is the first of several planned OnTrak-A expansions in 2020.
Catasys, Inc. , a leading AI and technology-enabled healthcare company, today announced the appointment of Mr. Curt Medeiros as President and Chief Operating Officer.
Catasys, Inc. , a leading AI and technology-enabled healthcare company, today announced the appointment of Mr. Gustavo Giraldo to its Board of Directors, replacing Ms.
It's been a good week for Catasys, Inc. (NASDAQ:CATS) shareholders, because the company has just released its latest...
SANTA MONICA, Calif.-- -- Q3 2019 Record Revenue of $8.8 Million, Up 102% Year over Year and 15% from Q2 2019 Total Outreach Pool of Eligible Members of 140,000 in Q3 2019, Up 26% from 112,000 at Q2 2019 Net New Enrolled Members of 1,473 in Q3 2019, up 366% from 316 in the Same Period of Prior Year Secured $45 Million in Debt Financing from Goldman Sachs to Support Company’s Accelerating Growth Company ...
Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment process because our research has shown that the elite investors' consensus returns have been exceptional. In the following paragraphs, we find out […]
Catasys, Inc. , a leading AI and technology-enabled healthcare company, today announced that the Company will be releasing financial results for its third quarter ended September 30, 2019, after the closing of the stock market on Wednesday, November 13, 2019.
If you own shares in Catasys, Inc. (NASDAQ:CATS) then it's worth thinking about how it contributes to the volatility...
Catasys, Inc. (CATS) (“Catasys” or the “Company”), a leading AI and technology-enabled healthcare company, today announced that Mr. Terren Peizer, the Company’s Chairman and CEO, is scheduled to present at the 28th Annual Healthcare Conference on Tuesday, November 12, 2019, at 4:10 p.m. MST. Catasys, Inc. is a leading AI and technology-enabled healthcare company whose mission is to help improve the health and save the lives of as many people as possible. By combining predictive analytics with human engagement, Catasys delivers improved member health and validated outcomes and savings to healthcare payers.
Low float stocks can be some of the most volatile stocks in the market. If you mix in a short squeeze, the potential short-term gains in a low float stock can be extreme. A stock’s float is the number ...
On Wednesday, August 14, Catasys (NASDAQ: CATS ) will report its last quarter's earnings. Here is Benzinga's preview of the company's release. Earnings and Revenue Sell-side analysts are expecting Catasys's ...
BERKELEY, Calif., and VANCOUVER, British Columbia, Aug. 12, 2019 -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage.
Catasys (CATS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.